Burns - Pipeline Review, H2 2017

Burns - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Burns - Pipeline Review, H2 2017, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to bodys tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Burns - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 4, 1, 14, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Burns (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Introduction 5
Global Markets Direct Report Coverage 5
Burns - Overview 6
Burns - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Burns - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Burns - Companies Involved in Therapeutics Development 23
AlgiPharma AS 23
Alliance Pharma Plc 23
Amarantus Bioscience Holdings Inc 24
American Gene Technologies International Inc 24
Anterogen Co Ltd 25
CytoTools AG 25
Destiny Pharma Ltd 26
Lakewood-Amedex Inc 26
Madam Therapeutics BV 27
MediWound Ltd 27
Phagelux Inc 28
Phosphagenics Ltd 28
Se-cure Pharmaceuticals Ltd 29
Stratatech Corp 29
USV Pvt Ltd 30
Burns - Drug Profiles 31
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile 31
A-3APO - Drug Profile 32
AG-110 - Drug Profile 34
albumin (recombinant) - Drug Profile 35
AyuV-25 - Drug Profile 36
Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile 37
bromelains - Drug Profile 38
Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile 42
Cell Therapy for Dermatology and Immunology - Drug Profile 44
ENERGIF-711 - Drug Profile 46
epidermal growth factor biosimilar - Drug Profile 47
Gene Therapy for Burns - Drug Profile 48
IMSP-001 - Drug Profile 49
ISN-001 - Drug Profile 50
lidocaine hydrochloride - Drug Profile 52
Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile 53
Neu-2000 - Drug Profile 54
NJ-01SS - Drug Profile 56
Nu-2 - Drug Profile 57
Oligomer G for Burn Wounds - Drug Profile 58
P-12 - Drug Profile 59
P-148 - Drug Profile 60
PEP-04 - Drug Profile 61
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 62
Recombinant Protein to Agonize EPCR for Wounds and Burns - Drug Profile 63
SC-106 - Drug Profile 64
SFR-9X0125 - Drug Profile 65
silver sulfadiazine - Drug Profile 66
Small Molecules for Burns - Drug Profile 67
sodium hypochlorite - Drug Profile 68
SST-024 - Drug Profile 69
Vanadis-02 - Drug Profile 70
XF-70 - Drug Profile 71
Burns - Dormant Projects 72
Burns - Discontinued Products 74
Burns - Product Development Milestones 75
Featured News & Press Releases 75
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List Of Tables

Number of Products under Development for Burns, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Burns - Pipeline by AlgiPharma AS, H2 2017
Burns - Pipeline by Alliance Pharma Plc, H2 2017
Burns - Pipeline by Amarantus Bioscience Holdings Inc, H2 2017
Burns - Pipeline by American Gene Technologies International Inc, H2 2017
Burns - Pipeline by Anterogen Co Ltd, H2 2017
Burns - Pipeline by CytoTools AG, H2 2017
Burns - Pipeline by Destiny Pharma Ltd, H2 2017
Burns - Pipeline by Lakewood-Amedex Inc, H2 2017
Burns - Pipeline by Madam Therapeutics BV, H2 2017
Burns - Pipeline by MediWound Ltd, H2 2017
Burns - Pipeline by Phagelux Inc, H2 2017
Burns - Pipeline by Phosphagenics Ltd, H2 2017
Burns - Pipeline by Se-cure Pharmaceuticals Ltd, H2 2017
Burns - Pipeline by Stratatech Corp, H2 2017
Burns - Pipeline by USV Pvt Ltd, H2 2017
Burns - Dormant Projects, H2 2017
Burns - Dormant Projects, H2 2017 (Contd..1), H2 2017
Burns - Discontinued Products, H2 2017

List Of Figures

Number of Products under Development for Burns, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available